Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact sciences

ISIN: US30063P1057 , WKN: 590273

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Sarepta Therapeutics (SRPT) Down 6.2% Since Last Earnings Report: Can It Rebound?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cathie Wood Watch: Ark Buys Coinbase and Block

Her flagship Ark Innovation ETF has lost 46% during the past year but has rebounded 22% year to date.

Emergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cathie Wood Watch: Ark Buys Coinbase, Sells Exact Sciences

Wood's flagship Ark Innovation ETF has dropped 44% over the last year, but has rebounded 19% so far this year.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know

Exact Sciences (EXAS) closed at $66.28 in the latest trading session, marking a +1.33% move from the prior day.

Cathie Wood Watch: While Others Sell Block, Ark Is Buying

Wood's flagship Ark Innovation ETF has dropped 42% during the past year but has rebounded 21% so far this year.

Cathie Wood Watch: Ark Gets Back into Intuit

Wood's flagship Ark Innovation ETF has slumped 41% over the past year, but has rebounded 27% so far this year.

3 Stocks With Superior Potential for Super-Sized Gains in 2023

Stocks with potential are probably not everyone’s cup of tea right now. With talks of an impending recession, everyone is looking for safer options. However, Shelby Davis once famously said, “Invest for the long haul. Don’t get too greedy, and don’t get too scared.” Although stock indexes are lackluster, it’s important to think ahead to the next bull market, regardless of whether it’s imminent or further down the line. Focusing on the future will allow you to prepare your portfolio for the worst

Cathie Wood Watch, Blast from the Past: Ark Buys Microsoft

For Wood, buying shares of Microsoft is like you or I shifting some of our portfolio into cash during a time of danger.